Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition Brian K. ChenY. Tony YangCharles L. Bennett Current Opinion 16 November 2018 Pages: 1777 - 1781
A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension Arrigo F. G. CiceroMasanari KuwabaraClaudio Borghi Review Article 13 November 2018 Pages: 1783 - 1790
Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis Simona LattanziFrancesco BrigoMauro Silvestrini Systematic Review 03 November 2018 Pages: 1791 - 1804
Tapentadol Prolonged Release: A Review in Pain Management Emma D. Deeks Adis Drug Evaluation Open access 23 November 2018 Pages: 1805 - 1816
Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection Emma D. Deeks Adis Drug Evaluation Open access 20 November 2018 Pages: 1817 - 1828
Fremanezumab: First Global Approval Sheridan M. Hoy AdisInsight Report Open access 08 November 2018 Pages: 1829 - 1834
Cemiplimab: First Global Approval Anthony MarkhamSean Duggan AdisInsight Report 19 November 2018 Pages: 1841 - 1846
Duvelisib: First Global Approval Hannah A. Blair AdisInsight Report 14 November 2018 Pages: 1847 - 1853
Correction to: Elagolix: First Global Approval Yvette N. Lamb Correction Open access 15 November 2018 Pages: 1855 - 1855